This trial is approved for marketing!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Recurrent Ovarian Cancer
and you are
over 18
years old
-
The phase for this study is not defined.
Show me locations

The purpose

This is an expanded access program (EAP) for eligible patients with Recurrent Ovarian Cancer. This program is designed to provide access to niraparib prior to approval by the US Food and Drug Administration (FDA). To be eligible, patients with Recurrent Ovarian Cancer following a partial (PR) or complete response (CR) to their most recent platinum-based chemotherapy and must have experienced a PR or CR after the penultimate (next to last) platinum-based chemotherapy for at least 6 months without disease progression after this chemotherapy.

Provided treatments

  • Drug: Niraparib

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT03025867. The sponsor of the trial is Tesaro, Inc. and it is looking for 0 volunteers for the current phase.
Official trial title:
Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian Cancer